Merus is a clinical-stage oncology biotechnology company that develops multispecific antibody therapeutics designed to treat cancer using its proprietary antibody platforms.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| George Soros / Soros Fund Mgmt | 30 | New buy | 405,000 | $38,130,750 | 0.5% |
| Louis Bacon / Moore | 55 | New buy | 30,200 | $2,843,330 | 0.0% |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-07-02.